APstem’s proprietary and patented AHPSC™ technology
Stem cell therapy is emerging as a new treatment for many incurable diseases.
Stem cells can self-renew and further differentiate into tissue-specific cells, indicating their potential to repair and regenerate damaged tissues or organs. APstem Therapeutics is developing first in class, off-the-shelf adult high-plasticity stem cell (AHPSC) therapies with proprietary methods for cell isolation, activation, expansion, analysis, and long-term storage.
AHPSCs have been induced in vitro to differentiate into cells representing typical tissues of the three germ layers. In vivo AHPSCs demonstrate significant regenerative ability and can heal damaged tissues. Tumorigenicity studies and treatment of thousands of animals indicate that AHPSCs do not form tumors.
The AHPSCs possess the potential to cure a wide range of severe and life-threatening diseases. Rapid and broad access to consistent, durable stem cell therapies for pre-clinical and clinical demand.
AHPSCs exhibit high plasticity, enabling them to differentiate into various cell types derived from three germ layers, making them highly suitable for tissue repair and regeneration. Given the urgent demand, we have chosen to initially focus on treating diabetes and its complications, and neurodegenerative diseases, with the aim of addressing age-related health challenges in the near future.
Significant advantages of AHPSCs include:
Convenient Source:
AHPSCs are obtained from peripheral blood of healthy donors.
Remarkable Efficacy
AHPSCs demonstrate efficient differentiation and powerful therapeutic capabilities, enabling them to repair various types of damaged tissues.
Immunocompatibility
AHPSCs are an off-the-shelf cell product for allogeneic transplantation without the need for tissue matching or immunosuppression.
Safety Profile
AHPSCs are not tumorigenic in safety assessments with no notable toxicity.